DBV Technologies Logo

DBV Technologies

ISIN

FR0010417345

Ticker

DBV

Sector

Health Care

Sub-Industry

Biotechnology

Country

France

Year Founded

2002

About DBV Technologies

Company Description

DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential clinical applications. Viaskin is based on epicutaneous immunotherapy, or EPIT™, a method of delivering biologically active compounds to the immune system through intact skin. With this new class of patch-based, non-invasive product candidates, the Company is dedicated to safely transforming the care of food-allergic patients. DBV’s food allergy programs include ongoing clinical trials of Viaskin™ Peanut in children. In addition to food allergies, Viaskin technology is also being investigated as a treatment option for other immunological disorders. Additional applications for Viaskin, such as use as a diagnostic tool for non-IgE-mediated milk allergy or as a non-invasive method for delivering vaccines against certain diseases, are also being investigated. DBV Technologies has global headquarters in Montrouge, France, and North American operations in Summit, NJ.

Headcount

92

Served Area

Worldwide

Headquarters

177-181 Avenue Pierre Brossolette
92120, Montrouge
France

Financial statements

Download as Excel
Line item in (usd) 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Assets N/A 272,019,000.00 146,323,000.00 246,494,000.00
Noncurrent Assets N/A 64,645,000.00 31,807,000.00 23,386,000.00
Property Plant And Equipment N/A 24,792,000.00 18,146,000.00 15,096,000.00
Intangible Assets Other Than Goodwill N/A 41,000.00 22,000.00 10,000.00
Other Noncurrent Assets N/A 29,935,000.00 6,868,000.00 5,824,000.00
Current Assets N/A 207,374,000.00 114,516,000.00 223,108,000.00
Trade And Other Current Receivables N/A 2,230,000.00 0.00 N/A
Current Trade Receivables N/A N/A 0.00 0.00
Cash and cash equivalents 193,255,000.00 196,352,000.00 77,301,000.00 209,194,000.00
Other Current Assets N/A 8,792,000.00 37,215,000.00 13,914,000.00
Equity And Liabilities N/A 272,019,000.00 146,323,000.00 246,494,000.00
Issued Capital N/A 6,518,000.00 6,538,000.00 10,720,000.00
Retained Earnings Profit Loss For Reporting Period N/A N/A -98,052,000.00 -96,008,000.00
Share Premium N/A 996,849,000.00 199,801,000.00 294,881,000.00
Equity Attributable To Owners Of Parent N/A 205,388,000.00 99,029,000.00 194,497,000.00
Noncurrent Liabilities N/A 13,918,000.00 15,896,000.00 22,476,000.00
Noncurrent Provisions N/A 2,404,000.00 6,602,000.00 16,591,000.00
Other Noncurrent Liabilities N/A 475,000.00 2,147,000.00 4,735,000.00
Longterm Borrowings N/A 543,000.00 0.00 0.00
Current Liabilities N/A 52,713,000.00 31,398,000.00 29,521,000.00
Current Provisions N/A 5,016,000.00 4,095,000.00 3,944,000.00
Trade And Other Current Payables N/A 20,338,000.00 11,429,000.00 N/A
Trade And Other Current Payables To Trade Suppliers N/A N/A 11,429,000.00 14,473,000.00
Other Current Liabilities N/A 22,927,000.00 12,361,000.00 9,210,000.00
Current Borrowings And Current Portion Of Noncurrent Borrowings N/A 724,000.00 510,000.00 0.00
Line item in (usd) 01.01.2020/
01.01.2021
01.01.2021/
01.01.2022
01.01.2022/
01.01.2023
Revenue 0.00 0.00 N/A
Other Revenue 11,276,000.00 5,708,000.00 N/A
Revenue From Contracts With Customers N/A 0.00 0.00
Other Income N/A 5,708,000.00 4,844,000.00
Profit Loss From Operating Activities -157,948,000.00 -98,264,000.00 -96,193,000.00
Finance Income 244,000.00 521,000.00 684,000.00
Finance Costs 1,971,000.00 690,000.00 429,000.00
Income Tax Expense Continuing Operations -10,000.00 -381,000.00 70,000.00
Profit (loss) -159,665,000.00 -98,052,000.00 -96,008,000.00
Line item in (usd) 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Profit (loss) N/A -159,665,000.00 -98,052,000.00 -96,008,000.00
Adjustments For Decrease Increase In Inventories N/A 2,327,000.00 0.00 0.00
Adjustments For Increase Decrease In Trade Account Payable N/A N/A -7,559,000.00 3,456,000.00
Adjustments For Sharebased Payments N/A -1,130,000.00 3,122,000.00 5,026,000.00
Other Adjustments For Noncash Items N/A 1,657,000.00 1,250,000.00 170,000.00
Cash Flows From Used In Operating Activities N/A -160,891,000.00 -104,058,000.00 -51,400,000.00
Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities N/A 55,000.00 604,000.00 8,000.00
Purchase Of Property Plant And Equipment Classified As Investing Activities N/A 2,788,000.00 910,000.00 754,000.00
Purchase Of Intangible Assets Classified As Investing Activities N/A 29,000.00 8,000.00 0.00
Cash Flows From Used In Investing Activities N/A -2,865,000.00 -433,000.00 -100,000.00
Proceeds From Issuing Shares N/A 150,449,000.00 794,000.00 194,471,000.00
Proceeds From Borrowings Classified As Financing Activities N/A 0.00 0.00 0.00
Repayments Of Borrowings Classified As Financing Activities N/A 303,000.00 689,000.00 474,000.00
Payments Of Lease Liabilities Classified As Financing Activities N/A 3,709,000.00 3,590,000.00 4,090,000.00
Other Inflows Outflows Of Cash Classified As Financing Activities N/A -36,000.00 -15,000.00 0.00
Cash Flows From Used In Financing Activities N/A 144,836,000.00 -3,910,000.00 189,854,000.00
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes N/A N/A -108,401,000.00 138,354,000.00
Effect Of Exchange Rate Changes On Cash And Cash Equivalents N/A 22,017,000.00 -10,650,000.00 -6,461,000.00
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes N/A -18,920,000.00 -108,401,000.00 N/A
Cash and cash equivalents 193,255,000.00 196,352,000.00 77,301,000.00 209,194,000.00

Please note that some sums might not add up.

Filings & Publications

  • Consolidated Report 2022 - Q4 French 🇫🇷
  • Consolidated Report 2021 - Q4 French 🇫🇷

Insider Trades

Date Trading entity / Person Association Trade type Volume
09.06.2022 None Other Other EUR 7,449,483.00

Capital Markets Information

ISIN

FR0010417345

LEI

969500PVBQFWQKVDMD80

Sub-Industry

Biotechnology

Listed Stock Exchange

Euronext Paris

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.